Theragent and CellVax Therapeutics Announce First Manufacturing Batch in Phase 2 Trial of FK-PC101, a Novel Personalized Cancer Immunotherapy

Posted on by

ARCADIA, Calif., Nov. 11, 2024 /PRNewswire/ — Theragent Inc., a comprehensive CDMO focused on advancing next-generation cell-based therapies, has announced a significant milestone for both Theragent and its sponsor client, CellVax Therapeutics Inc. This past week, Theragent produced the…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.